Gefitero 250mg Tablet

Gefitero 250mg Tablet may cause certain side effects. If side effects occur after administration or last longer than usual, contact your healthcare professional.

• Diarrhea
• Fever
• Allergic skin reaction
• Nausea and Vomiting
• Increase in liver enzyme levels
• Eye irritation
• Difficulty in breathing
• Abdominal pain
• Sore throat
• Redness around fingernails
• Unusual bleeding (in cough and urine), eye irritation or swelling of the ankles or feet ​

Depending on your health and body tolerance, the doctor will advise you on the dosage strength and frequency. Consume the entire ​Gefitero 250mg Tablet with water. Avoid cutting or crushing it. In a case of an overdose, seek immediate medical attention and get in touch with your doctor.

Gefitero 250mg tablet is an anticancer medicine that contains gefitinib as an active ingredient.

It works by blocking the action of a protein known as epidermal growth factor receptor (EGFR) that is responsible for the growth and multiplication of certain cancer cells.

Results in slowing down the progression of non-small cell lung cancer in patients with specific EGFR gene mutations.

​If a patient misses a dose of medicine, skip it and continue with the normal schedule. No need to double the dose ​

At our pharmacy, your health is our top priority. All of our medicines are safe, effective, and approved by leading health authorities. We partner exclusively with reliable and reputable manufacturers, ensuring the highest quality standards in every product we deliver.

Enjoy the convenience of fast home delivery, secure packaging, and affordable prices*—plus *special discounts on bulk orders. We’re proud to offer international shipping to a wide range of countries across Asia, Europe, Africa, the Americas, and beyond, making trusted healthcare accessible no matter where you are.

Whether you're a patient or a healthcare provider, you can order with confidence and compassion. Our goal is to ensure that quality healthcare reaches everyone, everywhere.


We currently ship to:

Barbados, Haiti, Trinidad and Tobago, Mexico, Bahamas, Ecuador, Peru, Chile, Brazil, Colombia, Philippines, U.K., USA, Kuwait, Saudi Arabia, UAE, Oman, Qatar, Japan, Ireland, Russia, China, France, Australia, Lithuania, Nigeria, Romania, Algeria, Canada, Singapore, Thailand, Hong Kong, Bahrain, Jordan, Indonesia, Hungary, Moldova, Bulgaria, Azerbaijan, Congo, Ethiopia, Lebanon, Morocco, Mozambique, South Korea, Sri Lanka, Belarus, Mongolia, Malaysia, Vietnam, Tunisia, Zambia, and Israel.
Experience the quality everyone’s talking about – order today!

Fukuoka. M., Yano. S., Giaccone. G., Tamura. T. Nakagawa. K., Douillard. J.‑Y., Nishiwaki. Y., Vansteenkiste. J., Kudoh. S., & Mizuuchi. H. (2024). Multi‑institutional randomized Phase II trial of gefitinib (Iressa, ZD1839) for previously treated patients with advanced non‑small‑cell lung cancer (IDEAL‑1). Journal of Clinical Oncology, 22(11), 2231–2239 - https://pubmed.ncbi.nlm.nih.gov/12748244/

Saraswati. E. N., Wulandari. L., Erawati. D., & Febriani. A. (2024). Comparison between the originator and me‑too drugs of first‑generation EGFR‑TKI in EGFR‑mutant NSCLC patients: A retrospective cohort study. International Journal of Research Publications. 147(1), 236–244.

Sim. E. H. A., Yang. I. A., Wood‑Baker. R., Bowman. R. V., & Fong. K. M. (2025). Gefitinib for advanced non‑small cell lung cancer. Cochrane Database of Systematic Reviews. 1(1),  https://doi.org/10.1002/14651858.

Wo. H., He. J., Zhao. Y., Yu. H., Chen. F., Yi. H. (2018). The Efficacy and Toxicity of Gefitinib in Treating Non-small Cell Lung Cancer: A Meta-analysis of 19 Randomized Clinical Trials. Journal of Cancer, 9(8), 1455-1465 - https://pmc.ncbi.nlm.nih.gov/articles/PMC5929091/

Xu. J.‑M., Li. Y.‑M., Liu. X.‑Q., Zhang. Y., Han. Y., Yang. W.‑W., & Song. S.‑T. (2024). Clinical observation of gefitinib for the treatment of 125 cases with advanced non‑small cell lung cancer. Zhonghua Zhong Liu Za Zhi. 29(1), 66–69.